GILD250103P104000
- 0.00
- 0.000.00%
Gilead Sciences Newsroom
Gilead Sciences, Inc. (NASDAQ:GILD) Is a Favorite Amongst Institutional Investors Who Own 86%
RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating
Hookipa Shareholder Gilead Sciences to Back Poolbeg Merger
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Citi's Themes: Top Stocks in AI, Leisure, Fin-tech, Video Gaming, Etc. Vs. Their SA Quant Ratings
Gilead Sciences, Inc. (GILD): A Bull Case Theory
Express News | Gilead's new HIV drug has been approved domestically: it requires administration twice a year, and trials show a 96% reduction in the infection rate.
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Gilead (GILD.US) has received approval for the long-acting HIV treatment "Lenacapavir" to be marketed in China.
The NMPA official website shows that Gilead (GILD.US) has received approval for the marketing application of its HIV therapy lenacapavir tablets and lenacapavir injection.
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Express News | The HIV long-acting therapy Lenacapavir, which is administered twice a year, has been approved in China.
Express News | Gilead's long-acting HIV therapy has been approved for sale in China, requiring administration only twice a year.
Is Gilead Sciences, Inc. (GILD) the Best Pharma Dividend Stocks to Buy In 2024?
Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.
Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.
Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Jim Cramer on Gilead Sciences, Inc. (GILD): 'I Don't Think The Business Is Worth As Much As The Stock Is Selling'
Gilead Sciences, Inc. (GILD) Is Attracting Investor Attention: Here Is What You Should Know